compound semaglutide risks of compounded products Semaglutide: Double-edged Sword with Risks

Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis

There is no clinical evidence supporting compounded semaglutide above 2.4 mg weekly or compounded tirzepatide above 15 mg weekly

Where to learn more For clinicians: seek continuing education on metabolic medicine, peptide pharmacology, and gutbrain interactions

Clinical trials and real-world data consistently show: Average weight loss of 1520% on semaglutide or tirzepatide Improvements in blood pressure, cholesterol, and blood sugar Reduced risk of developing type 2 diabetes and cardiovascular disease These outcomes are meaningful both for employee health and long-term cost avoidance